Do you want to read an article? Please log in or register.
Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic DMARDs in the treatment of moderate-to-severe rheumatoid arthritis.
Rheumatoid Arthritis
Related content
Autoimmune DiseaseRheumatoid Arthritis
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis
BioDrugs.
Nakayamada S, Kubo S, Iwata S, Tanaka Y
doi: 10.1007/s40259-016-0190-5
Melanoma and Skin CancerRheumatoid Arthritis
Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Arthritis Rheumatol.
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T
doi: 10.1002/art.39953.
Rheumatoid Arthritis
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial
Arthritis Care Res (Hoboken).
Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV
doi: 10.1002/acr.23004.
Rheumatoid Arthritis
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
Ann Rheum Dis.
Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C
doi: 10.1136/annrheumdis-
Rheumatoid Arthritis
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
Arthritis Res Ther.
Genovese MC, Fleischmann R, Kivitz A, Lee EB, van Hoogstraten H, Kimura T, St John G, Mangan EK, Burmester GR
doi: 10.1186/s13075-020-02194-z.
Further Publications Rheumatology
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Ann Rheum Dis
Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M, Zink A, Strangfeld A
doi: 10.1136/annrheumdis-2021-220651
Rheumatoid Arthritis
The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis
Arthritis Care Res (Hoboken).
Decarriere G, Barnetche T, Combe B, Gaujoux-Viala C, Lukas C, Morel J, Daien C
doi: 10.1002/acr.24195.
COMMENTED
Rheumatoid Arthritis
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Arthritis Res Ther.
Lukas C, Mary J, Debandt M, Daïen C, Morel J, Cantagrel A, Fautrel B, Combe B
doi: 10.1186/s13075-019-2020-x.
Further Publications Rheumatology
Impact of using concomitant conventional DMARDs on adherence to biologic DMARD treatment in rheumatoid arthritis: Multi-centre, population-based cohort study
Semin Arthritis Rheum
Dormuth CR, Fisher A, Hudson M, Austin PC, Ernst P, Bresee L, Chateau D, Tamim H, Paterson JM, Lafrance JP, Taylor-Gjevre RM, Platt RW, Canadian Network For Observational Drug Effect Studies Cnodes Investigators
doi: 10.1016/j.semarthrit.2021.08.002